SLC5A1 and Hyperglycemia: Consequently, diabetes-induced hyperglycemia or SGLT-2 inhibition increases the SGLT-1 inhibition-induced increase in glucose excretion, which provides the renal rationale for dual SGLT-1/2 inhibition.